VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations
The once-daily MET inhibitor tepotinib shrank tumours in about half of patients with MET exon 14-skipping lung cancer, detected either in tissue or in a blood test, supporting approval and the use of liquid biopsy to find the alteration.
Overview
Phase 2 study of 152 patients with advanced non-small-cell lung cancer with MET exon 14 skipping detected by liquid or tissue biopsy treated with tepotinib 500 mg daily.
Objective response by independent review was 46 percent overall (48 percent in liquid-biopsy and 50 percent in tissue-biopsy groups) with a median duration of response of 11.1 months; peripheral oedema was the main toxicity.
- Objective response 46 percent; median duration of response 11.1 months.
- Similar responses whether detected by liquid or tissue biopsy.
Tepotinib is an approved alternative to capmatinib for MET exon 14 lung cancer, and the trial validated circulating tumour DNA as a way to find the alteration.
- Single-arm; grade 3 or higher peripheral oedema in 7 percent.
Similar pages
not linked directly; found by shared links- TrialTepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Shares Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer.
- Key paperGEOMETRY mono-1: capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, New England Journal of Medicine.
- TermMET exon 14 skipping mutation
Shares Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer.
- TreatmentCapmatinib
Shares Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer.
- CompanyMerck KGaA (EMD Serono)
Shares Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer.